Abstract
Virologic Response among Key Populations Living With HIV following a Switch to Dolutegravir-Based Regimen in Southern Nigeria
Highlights
HIV/AIDS remains a major challenge to health and development in Nigeria
Despite great progress made towards achieving HIV epidemic control, Nigeria ranks second in global HIV burden based on the total number of people living with HIV (PLWH) Key population (KP) groups consisting of female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWIDs), transgender people (TG) and people in closed settings are disproportionately affected by the epidemic [1,2]
The results showed that more participants achieved virologic suppression at 3 months when participants were transitioned to to include dolutegravir based regimen (TLD) compared to tenofovir and lamivudine (TLE), more participants on TLD achieved untransmitable viral load level of < 200 c/ml in three months compared to untransmitable viral load level achieved while on TLE for a longer period of six months
Summary
HIV/AIDS remains a major challenge to health and development in Nigeria. Despite great progress made towards achieving HIV epidemic control, Nigeria ranks second in global HIV burden based on the total number of people living with HIV (PLWH) Key population (KP) groups consisting of female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWIDs), transgender people (TG) and people in closed settings (such as prisons) are disproportionately affected by the epidemic [1,2]. The NAIIS survey indicated that about 50% of people living with HIV (PLWH) in the country had achieved viral load suppression of HIV RNA of < 1000 copies per ml of plasma; a proportion much lower than the expected 90% target for the year 2020 [6,7]. Achieving viral load suppression is dependent on adherence to highly active anti-retroviral therapy (HAART) and the use of optimized antiretroviral (ARV) drug regimens which significantly improves treatment outcomes in PLWH [8]. Achieving optimal virologic suppression among key population groups is essential to HIV epidemic control. The aim of this study was to investigate the virologic outcome of key populations (KP) transitioned to dolutegravir-based regimen.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
